Challenges with bipolar disorder drug discovery

References

• Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67(1):1–8. doi:10.1097/01.psy.0000151489.36347.18.
   PubMed Web of Science ®Google Scholar
• Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–359. doi:10.1016/S2215-0366(14)70314-1.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–537.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–269.
   PubMed Web of Science ®Google Scholar
• Burdick KE, Braga RJ, Goldberg JF, et al. Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs. 2007;21(12):971–981.
   PubMed Web of Science ®Google Scholar
• Samalin L, Llorca PM, Giordana B, et al. Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYMUM study). J Affect Dis. 2014;159:94–102. doi:10.1016/j.jad.2014.02.023.
   PubMed Web of Science ®Google Scholar
• Weinstock LM, Gaudiano BA, Epstein-Lubow G, et al. Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res. 2014;216:24–30. doi:10.1016/j.psychres.2014.01.038.
   PubMed Web of Science ®Google Scholar
• Alsaif M, Haenisch F, Guest PC, et al. Challenges in drug target discovery in bipolar disorder. Expert Opin Ther Targets. 2013;17(5):565–577. doi:10.1517/14728222.2013.771169.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. doi:10.1056/NEJMra050100.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Tanious M, Das P, et al. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27(2):135–153. doi:10.1007/s40263-013-0039-0.
   PubMed Web of Science ®Google Scholar
• Hoertel N, De Maricourt P, Gorwood P. Novel routes to bipolar disorder drug discovery. Expert Opin Drug Discov. 2013;8(8):907–918. doi:10.1517/17460441.2013.804057.
   PubMed Web of Science ®Google Scholar
• Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG. Drugs under early investigation for the treatment of bipolar disorder. Expert Opin Investig Drugs. 2015;24:477–490. doi:10.1517/13543784.2015.1019061.
   PubMed Web of Science ®Google Scholar
• Chen S-L, Lee S-Y, Chang Y-H, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol. 2014;24:1753–1759. doi:10.1016/j.euroneuro.2014.09.001.
   PubMed Web of Science ®Google Scholar
• Norris ER, Burke K, Correll JR, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord. 2013;144:141–147. doi:10.1016/j.jad.2012.06.023.
   PubMed Web of Science ®Google Scholar
• Du J, Wei Y, Liu L, et al. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci USA. 2010;107(25):11573–11578. doi:10.1073/pnas.0913138107.
   PubMed Web of Science ®Google Scholar
• Chen W, Gaisina I, Gunosewoyo H, et al. Structure-guided design of a highly selective glycogen synthase kinase-3β inhibitor: a superior neuroprotective pyrazolone showing antimania effects. ChemMedChem. 2011;6(9):1587–1592. doi:10.1002/cmdc.201100231.
   PubMed Web of Science ®Google Scholar
• Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332.
   PubMed Web of Science ®Google Scholar
• Schroeder FA, Lewis MC, Fass DM, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE. 2013;8(8):e71323. doi:10.1371/journal.pone.0071323.
   PubMed Web of Science ®Google Scholar
• Resende WR, Valvassori SS, Réus GZ, et al. Effects of sodium butyrate in animal models of mania and depression: implications as a new mood stabilizer. Behav Pharmacol. 2013;24(7):569–579. doi:10.1097/FBP.0b013e32836546fc.
   PubMed Web of Science ®Google Scholar
• Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci. 2014;5(6):459–467. doi:10.1021/cn500058v.
   PubMed Web of Science ®Google Scholar
• Effects of pentazocine versus lorazepam or placebo on manic symptoms; [ cited 2014 Nov 10]. Available from: clinicaltrials.gov/ct2/show/results/NCT00431184?term=pentazocine&rank=1
   Google Scholar
• Armani F, Andersen ML, Galduróz JCF. Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology. 2014;231:639–649. doi:10.1007/s00213-013-3397-x.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Henter ID, Zarate CA. New targets for rapid antidepressant action. Prog Neurobiol. 2016. [ Published online 2015 Dec 23. doi:10.1016/j.pneurobio.2015.12.001.
   Google Scholar
• McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015;9:CD011611.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Dis. 2011;135:389–394. doi:10.1016/j.jad.2011.06.005.
   PubMed Web of Science ®Google Scholar
• Brennan BP, Jensen JE, Hudson JI, et al. A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol. 2013;33(5):627–635. doi:10.1097/JCP.0b013e31829a83f5.
   PubMed Web of Science ®Google Scholar
• Sanches M, Bauer IE, Galvez JF, et al. The management of cognitive impairment in bipolar disorder: current status and perspectives. Am J Ther. 2015;22:477–486. doi:10.1097/MJT.0000000000000120.
   PubMed Web of Science ®Google Scholar
• Bouaziz M, Ambroise C, Guedj M. Accounting for population stratification in practice: a comparison of the main strategies dedicated to genome-wide association studies. PLoS One. 2011;6(12):e28845. doi:10.1371/journal.pone.0028845.
   PubMed Web of Science ®Google Scholar
• Soreca I, Fagiolini A, Frank E, et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res. 2008;42(11):956–961. doi:10.1016/j.jpsychires.2007.10.009.
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Lavaud P, et al. Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2013;74(3):265–270. doi:10.4088/JCP.12m07935.
   PubMed Web of Science ®Google Scholar